SVRA (Savara, Inc.) Stock | Pipeline, Insider Trades & Financials

Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Savara, Inc.

$5.26

-0.01 (-0.19%)

D 37Pipeline Score Richly Valued Pharma · Commercial

Market Cap

1.03 B

EPS

-0.56

P/E Ratio

Value Trade

9.51 M

SEC Financials

Q1 2026

Dilution Risk
25%
R&D Expenses
23.40 M
Operating CF
-33.05 M

Total Assets
221.65 M
Total Liabilities
45.61 M
Equity
176.04 M
D/E Ratio
12,345

-2.52 %

Week

-4.92 %

1 Month

-11.46 %

3 Month

7.73 %

6 Month

206.1 %

5 Year

-99.77 %

All Time

Cash Data

Stable

Cash Position
202.77 M
Monthly Burn
11.02 M
Runway
17.4 mo
Burn Trend
Accelerating
SEC Filing
May 12, 2026

Overview

Volume

1.25 M

52 Week Range

1.89 - 7.01

% held by Insiders

47.96 %

% held by Institutions

58.93 %

Enterprise Value

856.07 M

Total Shares

203.37 M

Short %

23.12 %

Float Shares

130.57 M

Company Description

HQ: 6836 BEE CAVE ROAD, AUSTIN, TX...

Employees:70

https://www.savarapharma.com

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
PDUFA Date example	MOLBREEVI (molgramostim inhalation solution) autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	PDUFA	—	Subscribe to access the data.	Biologics	Rare Diseases
PDUFA Date example	MOLBREEVI (molgramostim inhalation solution) autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	PDUFA	—	Subscribe to access the data.	Biologics	Rare Diseases
PDUFA Date example	MOLBREEVI (molgramostim inhalation solution) autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	PDUFA	—	Subscribe to access the data.	Biologics	Rare Diseases

Unlock Upcoming Catalyst data

Drug Pipeline Intelligence

D37

Pipeline Score

$44M

Pipeline Value

Richly Valued

Valuation Signal

Drugs Scored

0.0x

rNPV / MCap

Top 50%

Micro Cap

(rank 453 of 905)

Percentile Rank

Savara, Inc. faces pipeline headwinds (37/100), with $138M risk-adjusted pipeline value, led by molgramostim in Mycobacterium Infections, Nontuberculous (Phase 2).

Showing 1 of 1 assets

Drug	Indication	Phase	NCT ID	PTRS	rNPV	Status	Enrollment	Velocity	Design	Completion	ML Signal	Last Change
Molgramostim Small molecule	Autoimmune Pulmonary Alveolar Proteinosis	Phase 3	NCT04544293	58%	$97M	ACTIVE NOT_RECRUITING	308	SLOW	B (71)	May 30, 2027	MODERATE_RISK	LOW May 26, 2026

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
Molgramostim	Autoimmune Pulmonary Alveolar Proteinosis	Phase 3	2025-08-21	At Week 24, DLco% improved by 9.8% in the molgramostim group vs. 3.8% in placebo (estimated treatment difference, 6.0%; P<0.001).,At Week 48, DLco% improved by 11.6% in the molgramostim group vs. 4.7% in placebo (estimated treatment difference, 6.9%; P<0.001).,SGRQ Total score reduction at Week 24: -11.5 points in molgramostim vs. -4.9 points in placebo (P=0.007).,SGRQ Activity score reduction at Week 24: -13.0 points in molgramostim vs. -5.2 points in placebo.,Peak-METs change at Week 48: 1.1 in molgramostim vs. 0.6 in placebo (estimated treatment difference, 0.6).,Mean reduction in GGO score at Week 24: -2.1 in molgramostim vs. -1.1 in placebo.	New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Read More
Molgramostim	Autoimmune Pulmonary Alveolar Proteinosis	Phase 3	2025-08-21	At Week 24, DLco% improved by 9.8% in the molgramostim group vs. 3.8% in placebo (estimated treatment difference, 6.0%; P<0.001).,At Week 48, DLco% improved by 11.6% in the molgramostim group vs. 4.7% in placebo (estimated treatment difference, 6.9%; P<0.001).,SGRQ Total score reduction at Week 24: -11.5 points in molgramostim vs. -4.9 points in placebo (P=0.007).,SGRQ Activity score reduction at Week 24: -13.0 points in molgramostim vs. -5.2 points in placebo.,Peak-METs change at Week 48: 1.1 in molgramostim vs. 0.6 in placebo (estimated treatment difference, 0.6).,Mean reduction in GGO score at Week 24: -2.1 in molgramostim vs. -1.1 in placebo.	New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Read More
Molgramostim	Autoimmune Pulmonary Alveolar Proteinosis	Phase 3	2025-08-21	At Week 24, DLco% improved by 9.8% in the molgramostim group vs. 3.8% in placebo (estimated treatment difference, 6.0%; P<0.001).,At Week 48, DLco% improved by 11.6% in the molgramostim group vs. 4.7% in placebo (estimated treatment difference, 6.9%; P<0.001).,SGRQ Total score reduction at Week 24: -11.5 points in molgramostim vs. -4.9 points in placebo (P=0.007).,SGRQ Activity score reduction at Week 24: -13.0 points in molgramostim vs. -5.2 points in placebo.,Peak-METs change at Week 48: 1.1 in molgramostim vs. 0.6 in placebo (estimated treatment difference, 0.6).,Mean reduction in GGO score at Week 24: -2.1 in molgramostim vs. -1.1 in placebo.	New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Read More

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in SVRA

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

Biotech Analyst Ratings

Symbol

Firm

Rating

Action

Price Target

Upside

date

SVRA

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

SVRA

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

SVRA

Example Securities

Buy

Initiated

$150.00

+25%

2026-01-15

Unlock Biotech Analyst Ratings data

SVRA Stock Forecast & Analyst Consensus

BUY

Analyst Ratings

Buy65.0%

Hold25.0%

Sell10.0%

Price Target Trend

Average$24.00

Low$18.00

High$32.00

Unlock Price Target Trend

SVRA Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv
2026-07-17			0.00			0	-	-	-	-	-	-
2026-07-17			0.00			0	-	-	-	-	-	-
2026-07-17			0.00			0	-	-	-	-	-	-

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

Latest Savara, Inc. (SVRA) News & Alerts

Sunday, June 14, 2026

(%)

+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position

How SVRA ranks across every disease it competes in

No competitive intelligence available for SVRA.

Recent Updates

Recently added Catalysts

$5.26

SEC Financials

Cash Data

Overview

Company Description

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in SVRA

Biotech Analyst Ratings

SVRA Stock Forecast & Analyst Consensus

SVRA Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Latest Savara, Inc. (SVRA) News & Alerts

Demo Biotech Announces Positive Phase 3 Results

Competitive Position

Indication landscape

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

$5.26

SEC Financials

Cash Data

Overview

Company Description

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in SVRA

Biotech Analyst Ratings

SVRA Stock Forecast & Analyst Consensus

SVRA Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Latest Savara, Inc. (SVRA) News & Alerts

Demo Biotech Announces Positive Phase 3 Results

Competitive Position